Occupancy of Dopamine D2 and D3 Receptors by a Novel D3 Partial Agonist BP1. 4979: A [11C]-(+)-PHNO PET Study in Humans

Bernard Le Foll , Patricia Di Ciano , Esmaeil Mansouri , Alan A Wilson
NEUROPSYCHOPHARMACOLOGY 43 S453 -S454

2017
TETRAHEDRON: ASYMMETRY REPORT NUMBER 59

OB Sutcliffe , MR Bryce , GJA Conceiçao , PJS Moran
Tetrahedron: Asymmetry 14 ( 16)

Anxiogenic effects of CCK agonists in a nonhuman primate model: Central or peripheral

RM Palmour , C Durieux , BP Roques , P Bertrand
CCK 93 19 -22

9
1993
Preparation of 1-bis (aryl) methyl-3-(alkylsulfonyl) arylmethyleneazetidines as cannabinoid CB1 receptor antagonists

S Mignani , O Hittinger , D Archard , H Bouchard
Chemical Abstracts. France: Aventis Pharma SA 236982s -236982s

8
2000
From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

Alain Commerçon , Jean-Dominique Bourzat , Jacques Lavayre , Clive Brealey
Humana Press 115 -144

2001
Novel arylpiperazine derivatives

Marcel Morvan , Jeanne-Marie Lecomte , Marc Capet , Isabelle Berrebi-Bertrand

2008
N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant

Franco Manfre , Jean-Dominique Bourzat , Claude Cotrel , Claude Guyon

1991
Derives de glycinamide, leur preparation et les medicaments les contenant

Franco Manfre , Jean-Dominique Bourzat , Claude Cotrel , Claude Guyon

1991
Derives de n-phenyl glycinamide, leur preparation et les medicaments les contenant

Franco Manfre , Jean-Dominique Bourzat , Claude Cotrel , Claude Guyon

1991
1991
Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists

Olivia Poupardin-Olivier , Isabelle Berrebi-Bertrand , Jeanne-Marie Lecomte , Jean-Charles Schwartz
Bioorganic & Medicinal Chemistry 21 ( 15) 4526 -4529

13
2013
Synthesis and evaluation of amides surrogates of dopamine D3 receptor ligands.

Mickaël Jean , Jacques Renault , Nicolas Levoin , Denis Danvy
Bioorganic & Medicinal Chemistry Letters 20 ( 18) 5376 -5379

5
2010
Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity

Nicolas Levoin , Olivier Labeeuw , Thierry Calmels , Olivia Poupardin-Olivier
Bioorganic & Medicinal Chemistry Letters 21 ( 18) 5378 -5383

13
2011
Novel and highly potent histamine H3 receptor ligands. Part 2: Exploring the cyclohexylamine-based series

Olivier Labeeuw , Nicolas Levoin , Olivia Poupardin-Olivier , Thierry Calmels
Bioorganic & Medicinal Chemistry Letters 21 ( 18) 5384 -5388

9
2011
Refined docking as a valuable tool for lead optimization: application to histamine H3 receptor antagonists.

Nicolas Levoin , Thierry Calmels , Olivia Poupardin-Olivier , Olivier Labeeuw
Archiv Der Pharmazie 341 ( 10) 610 -623

35
2008
Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.

Olivier Labeeuw , Nicolas Levoin , Xavier Billot , Denis Danvy
Bioorganic & Medicinal Chemistry Letters 26 ( 21) 5263 -5266

5
2016
Improving selectivity of dopamine D3 receptor ligands.

Marc Capet , Thierry Calmels , Nicolas Levoin , Denis Danvy
Bioorganic & Medicinal Chemistry Letters 26 ( 3) 885 -888

7
2016
Congo red protects against toxicity of β-amyloid peptides on rat hippocampal neurones

Marie-Claude Burgevin , Marylène Passat , Nadine Daniel , Marc Capet
Neuroreport 5 ( 18) 2429 -2432

39
1994
Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.

Marc Capet , Olivier Labeeuw , Nicolas Levoin , Olivia Poupardin-Olivier
Bioorganic & Medicinal Chemistry Letters 23 ( 9) 2548 -2554

4
2013